“Tildrakizumab for Moderate-to-Severe Plaque Psoriasis: An Evidence-Based Review”. 2021. Canadian Dermatology Today 2 (s03): 3–8. https://canadiandermatologytoday.com/article/view/2-s03-devani-prajapati.